Insight Brief
January 18, 2017

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

Immune repertoire profiling provides better outcomes for immuno-oncology development programs
To better predict patients likely to respond to immuno-therapeutics, biomarker evaluation has expanded to the use of molecular analysis and has evolved from a focus on single analyte biomarker testing to multiplex analysis, wherein multiple genes to whole exomes can be assessed.

Today, a variety of treatment modalities targeting the immune system require tailored broad-spectrum biomarker screening to characterize mutational changes and the effects they have on the ability of T cells to mount immune responses to tumor antigens. Learn more about immune repertoire sequencing and how understanding a patient's immune profile can benefit for your clinical development program.

Victor Weigman, Ph.D., Associate Director, Translational Genomics
Patrick Hurban, Ph.D., Scientific Advisor, Genomics; Senior Director and Global Head, Translational Genomics
Alan Wookey, B.Sc., Global Science Lead, Companion Diagnostics & Scientific Advisor, Oncology
Patrice Hugo, Ph.D., Chief Scientific Officer

Related Services:
Genomic Assays for Clinical Development

Identifying the right approach from a wealth of potential options

Gene expression for keeping pace with immuno-oncology breakthroughs and biomarker identification

When and how to use gene expression profiling

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Read More